Corline Biomedical AB (CLBIO.ST)
SEK 8.64
(-0.23%)
SEK 8.64
(-0.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.69 Million SEK | -170.69% |
| 2022 | 2.38 Million SEK | 134.68% |
| 2021 | -6.87 Million SEK | 5.43% |
| 2020 | -7.27 Million SEK | 23.69% |
| 2019 | -9.53 Million SEK | -40.33% |
| 2018 | -6.79 Million SEK | 13.01% |
| 2017 | -7.8 Million SEK | -49.61% |
| 2016 | -5.21 Million SEK | 7.59% |
| 2015 | -5.64 Million SEK | -130.99% |
| 2014 | -2.44 Million SEK | -2.58% |
| 2013 | -2.38 Million SEK | -195.14% |
| 2012 | -807.48 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.37 Million SEK | -163.91% |
| 2024 Q1 | -1.68 Million SEK | -185.76% |
| 2023 Q2 | -2.38 Million SEK | -328.38% |
| 2023 Q1 | 1.04 Million SEK | 194.63% |
| 2023 FY | - SEK | -115.18% |
| 2023 Q3 | 230 Thousand SEK | 109.66% |
| 2023 Q4 | 3000.00 SEK | -98.7% |
| 2022 Q4 | 354 Thousand SEK | -82.14% |
| 2022 FY | - SEK | 134.68% |
| 2022 Q3 | 1.98 Million SEK | 123.2% |
| 2022 Q2 | 888 Thousand SEK | 205.71% |
| 2022 Q1 | -840 Thousand SEK | 34.17% |
| 2021 Q1 | -1.4 Million SEK | -2822.92% |
| 2021 Q4 | -1.27 Million SEK | 38.09% |
| 2021 Q2 | -2.13 Million SEK | -52.39% |
| 2021 Q3 | -2.06 Million SEK | 3.6% |
| 2021 FY | - SEK | 5.43% |
| 2020 Q1 | -2.5 Million SEK | -18.5% |
| 2020 Q3 | -2.14 Million SEK | 16.49% |
| 2020 Q4 | -48 Thousand SEK | 97.77% |
| 2020 FY | - SEK | 23.69% |
| 2020 Q2 | -2.57 Million SEK | -2.67% |
| 2019 Q2 | -2.52 Million SEK | 14.94% |
| 2019 Q1 | -2.96 Million SEK | -77.65% |
| 2019 Q3 | -1.93 Million SEK | 23.47% |
| 2019 FY | - SEK | -40.33% |
| 2019 Q4 | -2.11 Million SEK | -9.53% |
| 2018 FY | - SEK | 13.01% |
| 2018 Q4 | -1.66 Million SEK | -13.54% |
| 2018 Q1 | -1.78 Million SEK | -4.88% |
| 2018 Q3 | -1.47 Million SEK | 21.39% |
| 2018 Q2 | -1.87 Million SEK | -4.88% |
| 2017 FY | - SEK | -49.61% |
| 2017 Q2 | -2.03 Million SEK | 33.97% |
| 2017 Q3 | -986 Thousand SEK | 51.6% |
| 2017 Q4 | -1.7 Million SEK | -72.41% |
| 2017 Q1 | -3.08 Million SEK | -102.43% |
| 2016 Q2 | -600 Thousand SEK | 66.31% |
| 2016 FY | - SEK | 7.59% |
| 2016 Q1 | -1.78 Million SEK | 13.88% |
| 2016 Q4 | -1.52 Million SEK | -15.98% |
| 2016 Q3 | -1.31 Million SEK | -119.0% |
| 2015 Q4 | -2.06 Million SEK | -95.48% |
| 2015 FY | - SEK | -130.99% |
| 2015 Q1 | -1.1 Million SEK | -102.79% |
| 2015 Q2 | -1.41 Million SEK | -27.99% |
| 2015 Q3 | -1.05 Million SEK | 25.36% |
| 2014 Q3 | -619.6 Thousand SEK | -17.99% |
| 2014 Q4 | -546 Thousand SEK | 11.88% |
| 2014 FY | - SEK | -2.58% |
| 2014 Q2 | -525.11 Thousand SEK | 0.0% |
| 2013 FY | - SEK | -195.14% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 99.54% |
| AcouSort AB (publ) | -16.7 Million SEK | 89.876% |
| Active Biotech AB (publ) | -43.88 Million SEK | 96.147% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 4126.286% |
| Amniotics AB (publ) | -27.14 Million SEK | 93.77% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 88.106% |
| BioArctic AB (publ) | 275.38 Million SEK | 100.614% |
| Camurus AB (publ) | 562.54 Million SEK | 100.301% |
| Cantargia AB (publ) | -284.31 Million SEK | 99.405% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 91.363% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 90.102% |
| Genovis AB (publ.) | 64.57 Million SEK | 102.619% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 98.528% |
| Mendus AB (publ) | -97.84 Million SEK | 98.272% |
| Kancera AB (publ) | -61.88 Million SEK | 97.268% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 93.686% |
| LIDDS AB (publ) | -39.67 Million SEK | 95.737% |
| Lipum AB (publ) | -37.11 Million SEK | 95.444% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 86.029% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 105.385% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 84650.0% |
| NextCell Pharma AB | -40.98 Million SEK | 95.874% |
| OncoZenge AB (publ) | 7.26 Million SEK | 123.273% |
| Saniona AB (publ) | -69.69 Million SEK | 97.574% |
| Simris Alg AB (publ) | -22.36 Million SEK | 92.438% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 99.467% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 99.4% |
| Xintela AB (publ) | -53.47 Million SEK | 96.838% |
| Ziccum AB (publ) | -20.34 Million SEK | 91.687% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 95.433% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 99.004% |
| CombiGene AB (publ) | -35.33 Million SEK | 95.215% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 98.799% |
| Intervacc AB (publ) | -68.98 Million SEK | 97.549% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 99.288% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 18.702% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 87.41% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 99.024% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 96.915% |
| Aptahem AB (publ) | -10 Million SEK | 83.106% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 114.642% |
| Fluicell AB (publ) | -25.91 Million SEK | 93.475% |
| Biovica International AB (publ) | -119.5 Million SEK | 98.585% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 95.995% |
| Abliva AB (publ) | -93.6 Million SEK | 98.194% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 99.47% |
| 2cureX AB (publ) | -35.13 Million SEK | 95.187% |
| I-Tech AB | 30.34 Million SEK | 105.573% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 99.763% |
| Cyxone AB (publ) | -20.41 Million SEK | 91.716% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 98.349% |
| Biosergen AB | 228 Thousand SEK | 841.667% |
| Nanologica AB (publ) | -62.11 Million SEK | 97.278% |
| SynAct Pharma AB | -222.7 Million SEK | 99.241% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 96.145% |
| BioInvent International AB (publ) | -312.7 Million SEK | 99.459% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 646.519% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 99.27% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 80.811% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 98.442% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 85.256% |